Abstract
EB virus reactivation is one of the common complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the fatality rate as 13.8%.Immune depression and chronic inflammation play key roles in EB virus replication.Besides, the mechanism of EB virus lytic replication modulated by telomere specific reverse transcriptase (TERT) have been explained by recent studies. With preemptive therapy, the EB virus related mortality had been decreased, but the time of intervention remains unclear. Rituximab and early reduction of immunosuppressive therapy are recommended as first-line treatment. Immunotherapy has achieved enormous progress as well. This article reviews literatures on the life cycle, risk factors, diagnosis and treatment of EB virus reactivation. Key words: Epstein-Barr virus infections; Hematopoietic stem cell transplantation; Immunosuppressive agents; Immunotherapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
